BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32099036)

  • 21. Characterization of clonal immunoglobulin heavy chain and I cell receptor gamma gene rearrangements during progression of childhood acute lymphoblastic leukemia.
    Marshall GM; Kwan E; Haber M; Brisco MJ; Sykes PJ; Morley AA; Toogood I; Waters K; Tauro G; Ekert H
    Leukemia; 1995 Nov; 9(11):1847-50. PubMed ID: 7475273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease.
    Szczepański T; Beishuizen A; Pongers-Willemse MJ; Hählen K; Van Wering ER; Wijkhuijs AJ; Tibbe GJ; De Bruijn MA; Van Dongen JJ
    Leukemia; 1999 Feb; 13(2):196-205. PubMed ID: 10025893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.
    van der Velden VH; Willemse MJ; van der Schoot CE; Hählen K; van Wering ER; van Dongen JJ
    Leukemia; 2002 May; 16(5):928-36. PubMed ID: 11986956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.
    Wu D; Emerson RO; Sherwood A; Loh ML; Angiolillo A; Howie B; Vogt J; Rieder M; Kirsch I; Carlson C; Williamson D; Wood BL; Robins H
    Clin Cancer Res; 2014 Sep; 20(17):4540-8. PubMed ID: 24970842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dynamic monitoring of minimal residual disease in acute lymphoid leukemia].
    Shan SL; Xing HY; Tian Z; Tang KJ; Rao Q; Wang M; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1404-8. PubMed ID: 22169292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of novel, recurrent genomic rearrangements as sensitive MRD targets in childhood B-cell precursor ALL.
    Zur Stadt U; Alawi M; Adao M; Indenbirken D; Escherich G; Horstmann MA
    Blood Cancer J; 2019 Nov; 9(12):96. PubMed ID: 31784504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Presence of leukemic clone-specific immunoglobulin heavy chain rearrangements in neonatal blood spots of children with B-cell precursor acute lymphoblastic leukemia.
    Kacanski N; Kolarovic J; Kostic T; Marjanovic I; Janic D; Pavlovic S; Karan-Djurasevic T
    Int J Lab Hematol; 2024 Apr; 46(2):303-311. PubMed ID: 37929321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-throughput sequencing of immunoglobulin heavy chain for minimal residual disease detection in B-lymphoblastic leukemia.
    Correia RP; Puga RD; Muto NH; Lee MLM; Torres DC; Hassan R; Bacal NS; Hamerschlak N; Campregher PV
    Int J Lab Hematol; 2021 Aug; 43(4):724-731. PubMed ID: 33393719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitation of leukemia clone-specific antigen gene rearrangements by a single-step PCR and fluorescence-based detection method.
    Mayer SP; Giamelli J; Sandoval C; Roach AS; Fevzi Ozkaynak M; Tugal O; Rovera G; Jayabose S
    Leukemia; 1999 Nov; 13(11):1843-52. PubMed ID: 10557060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chromosome 14 copy number-dependent IGH gene rearrangement patterns in high hyperdiploid childhood B-cell precursor ALL: implications for leukemia biology and minimal residual disease analysis.
    Csinady E; van der Velden VH; Joas R; Fischer S; de Vries JF; Beverloo HB; König M; Pötschger U; van Dongen JJ; Mann G; Haas OA; Panzer-Grümayer ER
    Leukemia; 2009 May; 23(5):870-6. PubMed ID: 19148138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A clinical perspective on immunoglobulin heavy chain clonal heterogeneity in B cell acute lymphoblastic leukemia.
    Fries C; Burack WR
    Leuk Res; 2018 Dec; 75():15-22. PubMed ID: 30445235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
    Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
    Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Profile of immunoglobulin heavy chain variable gene repertoires and highly selective detection of malignant clonotypes in acute lymphoblastic leukemia.
    Greenberg SJ; Choi Y; Ballow M; Du TL; Ward PM; Rickert MH; Frankel S; Bernstein SH; Brecher ML
    J Leukoc Biol; 1995 Jun; 57(6):856-64. PubMed ID: 7790768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Identification of immunoglobulin and T-cell receptor gene rearrangements--prerequisite for monitoring of minimal residual disease in Polish acute lymphoblastic leukemia patients based on European standards. Preliminary results].
    Dawidowska M; Derwich K; Szczepański T; Jółkowska J; Witt M; Wachowiak J
    Med Wieku Rozwoj; 2006; 10(1 Pt 2):323-34. PubMed ID: 17028396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
    Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
    Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study of minimal residual disease in B-cell lineage acute lymphoblastic leukemia of childhood, using clone-specific probes.
    Botsonis T; Tsangaris GT; Mikraki V; Tzortzatou-Stathopoulou F
    Anticancer Res; 1999; 19(3B):2211-20. PubMed ID: 10472333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
    van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
    Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
    Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-10
    Tembhare PR; Subramanian Pg PG; Ghogale S; Chatterjee G; Patkar NV; Gupta A; Shukla R; Badrinath Y; Deshpande N; Narula G; Rodrigues P; Girase K; Dhaliwal D; Prasad M; Shetty D; Banavali S; Gujral S
    Cytometry B Clin Cytom; 2020 Jan; 98(1):57-67. PubMed ID: 31197916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
    Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
    Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.